XML 186 R129.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (€) € in Millions | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
--- | --- | --- | ---
Level 1 |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | € 5,673 | € 6,737 | € 10,765
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | MSD contingent consideration (European vaccines business) |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Shire contingent consideration arising from the acquisition of Translate Bio |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Contingent consideration arising from acquisition of Amunix |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Other contingent consideration arising from business combinations and acquisitions |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 1 | Quoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 467 | 470 | 387
Level 1 | Unquoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 1 | Quoted debt securities |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 357 | 346 | 329
Level 1 | Unquoted debt securities not meeting the definition of equity instruments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 1 | Contingent consideration relating to divestments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 1 | Financial assets held to meet obligations under deferred compensation plans |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 688 | 572 | 512
Level 1 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 1 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 1 | Mutual fund investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 4,161 | 5,349 | 9,537
Level 2 |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 217 | 201 | 206
Total financial liabilities measured at fair value | 458 | 291 | 326
Level 2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 2 | MSD contingent consideration (European vaccines business) |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 2 | Shire contingent consideration arising from the acquisition of Translate Bio |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 2 | Contingent consideration arising from acquisition of Amunix |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 2 | Other contingent consideration arising from business combinations and acquisitions |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 2 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 121 | 164 | 232
Level 2 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 337 | 127 | 94
Level 2 | Quoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Unquoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Quoted debt securities |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Unquoted debt securities not meeting the definition of equity instruments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Contingent consideration relating to divestments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Financial assets held to meet obligations under deferred compensation plans |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 2 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 217 | 201 | 206
Level 2 | Mutual fund investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 1,717 | 964 | 967
Total financial liabilities measured at fair value | 641 | 709 | 779
Level 3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 26
Level 3 | MSD contingent consideration (European vaccines business) |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 72 | 127 | 204
Level 3 | Shire contingent consideration arising from the acquisition of Translate Bio |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 568 | 441 | 380
Level 3 | Contingent consideration arising from acquisition of Amunix |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 137 | 165
Level 3 | Other contingent consideration arising from business combinations and acquisitions |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 1 | 4 | 4
Level 3 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 3 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial liabilities measured at fair value | 0 | 0 | 0
Level 3 | Quoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 | Unquoted equity investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 1,092 | 618 | 549
Level 3 | Quoted debt securities |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 | Unquoted debt securities not meeting the definition of equity instruments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 339 | 132 | 115
Level 3 | Contingent consideration relating to divestments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 286 | 214 | 303
Level 3 | Financial assets held to meet obligations under deferred compensation plans |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 | Non-current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 | Current derivatives |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | 0 | 0 | 0
Level 3 | Mutual fund investments |  |  |
Disclosure of information on income statement [line items] |  |  |
Total financial assets measured at fair value | € 0 | € 0 | € 0

X
- Definition The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 25 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 35H -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 35M -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard -URIDate 2023-03-23 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 35N -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard -URIDate 2023-03-23 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 35I -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_FinancialAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 25 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_FinancialLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure of information on income statement line items. + References No definition available. + Details
Name: | sny_DisclosureOfInformationOnIncomeStatementLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_ContingentConsiderationArisingFromTheAcquisitionOfAmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_OtherContingentConsiderationArisingFromBusinessCombinationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_NonCurrentDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfLiabilitiesAxis=sny_CurrentDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_QuotedEquityInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_UnquotedEquityInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_QuotedDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_UnquotedDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_ContingentConsiderationRelatingToDivestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_FinancialAssetsHeldToMeetObligationsUnderDeferredCompensationPlansMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_NonCurrentDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_CurrentDerivativesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfAssetsAxis=sny_MutualFundInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |